Relevant bibliographies by topics / Cancer Register

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer Register'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer Register.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer Register"

1

Xie, Shao-Hua, Giola Santoni, Fredrik Mattsson, Eivind Ness-Jensen, and Jesper Lagergren. "Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH)." BMJ Open 9, no. 1 (January 2019): e023155. http://dx.doi.org/10.1136/bmjopen-2018-023155.

Full text
Abstract:
PurposeThe Swedish Prescribed Drugs and Health Cohort (SPREDH) is a Swedish population-based cohort based on data from four nationwide health data registers, created with the aim of investigating how the use of selected medications influences cancer risk and other outcomes.ParticipantsThe cohort includes 8 421 115 users of selected common medications who have been followed-up for a total of 82 281 720 person-years from 1 July 2005 to 31 December 2015.Finding to dateThe data in SPREDH were prospectively collected from the following national health data registers in Sweden: Prescribed Drug Register, Patient Register, Cancer Register and Causes of Death Register. Data on basic patient characteristics, use of the selected common medications, healthcare utilisation, diagnoses (including detailed information on cancers), and dates and causes of death are available for all cohort participants. The cohort currently includes 801 766 incident cancer cases.Future plansThe data in SPREDH can be used for various types of epidemiological research, particularly for examining how the use of the selected medications influences disease risk and other outcomes. We are initially planning cohort studies and nested case-control studies on selected medications in relation to the risk and prognosis of oesophageal and gastric cancers.
APA, Harvard, Vancouver, ISO, and other styles
2

Häggström, Christel, Fredrik Liedberg, Oskar Hagberg, Firas Aljabery, Viveka Ströck, Abolfazl Hosseini, Truls Gårdmark, et al. "Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)." BMJ Open 7, no. 9 (September 2017): e016606. http://dx.doi.org/10.1136/bmjopen-2017-016606.

Full text
Abstract:
PurposeTo monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).ParticipantsThe SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.Findings to dateStudies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.Future plansThe SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.
APA, Harvard, Vancouver, ISO, and other styles
3

Bouhidel, Mohamed Larbi, Fayçal Beichi, Atika Bouhidel, Hachani Khadraoui, Imene Benamira, Mahdia Saidi, Abdelouahab Maaref, and Hocine Bounecer. "Cancer register in the Wilaya of Batna. The 2011 report." Batna Journal of Medical Sciences (BJMS) 2, no. 2 (December 30, 2012): 126–28. http://dx.doi.org/10.48087/bjmsoa.2015.2205.

Full text
Abstract:
Le registre du cancer de la wilaya de Batna est un registre de population, couvrant 1.173.852 habitants en 2011 (estimation avec un taux d’accroissement annuel de 1,58% à partir du recensement général de la population et de l’habitat RGPH 2008). Au total, 768 nouveaux cas de cancer ont été notifiés ; ce qui représente une incidence standardisée de 78,2 cas pour 100 000 habitants. Les cancers les plus fréquents chez l’homme sont respectivement : le cancer broncho-pulmonaire (12,2 cas/100 000 hbts) suivi du cancer colorectal et du cancer de la vessie. Chez la femme, le cancer du sein occupe largement le premier rang (25,2 cas/100 000 hbts) ce qui représente plus de 30% des cancers chez la femme. En deuxième position, se trouve le cancer colorectal suivi des cancers de la vésicule biliaire et de la thyroïde. La pathologie tumorale chez l’enfant (0-14 ans), dont l’incidence standardisée est de 1,9 cas/100 000 habitants, est dominée par le cancer du sang et des organes lymphoïdes.
APA, Harvard, Vancouver, ISO, and other styles
4

Stenbeck, Magnus. "Swedish cancer register: corrected data." Lancet 355, no. 9211 (April 2000): 1279. http://dx.doi.org/10.1016/s0140-6736(05)74713-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fayers, Peter, Della Gibson, and Jean Mossman. "UKCCCR register of U.K. cancer trials." Controlled Clinical Trials 16, no. 3 (June 1995): 172–81. http://dx.doi.org/10.1016/0197-2456(94)00067-d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ganesan, S., D. Mehta, and L. Parvanta. "Cancer register documentation; are we accurate?" International Journal of Surgery 36 (November 2016): S52. http://dx.doi.org/10.1016/j.ijsu.2016.08.110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fayers, Peter M., and Tim Armitage. "Towards an International Register of Cancer Trials: The UKCCCR register of U.K. trials." European Journal of Cancer 29, no. 6 (January 1993): 907–12. http://dx.doi.org/10.1016/s0959-8049(05)80436-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rohde, D., D. Rohde, K. Miller, and K. Miller. "Register Uro-Onkologischer Studien." Oncology Research and Treatment 26, no. 4 (2003): 35–42. http://dx.doi.org/10.1159/000074744.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fayers, P. M. "The UKCCCR register of UK cancer trials." Clinical Oncology 7, no. 2 (January 1995): 72–76. http://dx.doi.org/10.1016/s0936-6555(05)80804-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Von Euler-Chelpin, My, Elsebeth Lynge, and Matejka Rebolj. "Register-based studies of cancer screening effects." Scandinavian Journal of Public Health 39, no. 7_suppl (July 2011): 158–64. http://dx.doi.org/10.1177/1403494811401479.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer Register"

1

Lindqvist, Rikard. "Hospital length of stay : register-based studies on breast-cancer surgery /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-312-4/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Westerberg, Marcus. "Diagnosing Metastatic Prostate Cancer Using PSA:A Register-Based Cohort Study with Missing Data." Thesis, Uppsala universitet, Tillämpad matematik och statistik, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-322012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Klaff, Rami. "Disease-Specific Survival in Prostate Cancer Patients : Results from the Scandinavian Prostate Cancer Group (SPCG) Trial No. 5 and Regional Cancer Register Data." Doctoral thesis, Linköpings universitet, Institutionen för klinisk och experimentell medicin, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-132385.

Full text
Abstract:
Introduction Prostate cancer (PCa) is the most common cancer among men in Sweden. The clinical course varies considerably, which makes it difficult to predict the prognosis in the individual case. In order to explore the early as well as the late course of the disease, large study groups and population-based cohorts are necessary. Aims To explore factors that influence the long-term outcome of men with low-risk tumours in a population-based register, to predict the long-term course, and to assess the mortality rate for men with prostate cancer (Paper I) To analyse long-term outcome and to investigate factors associated with long-term survival in patients with metastases to the skeleton (Paper II) To analyse early androgen deprivation treatment (ADT) failure and to define clinical predictors associated with short survival due to early ADT failure in prostate cancer patients with bone metastases (Paper III) To analyse the prognostic significance of the extent of bone metastases in relation to other pretreatment variables in prostate cancer patients, and to explore the impact of bone metastases on quality-of-life (Paper IV) Material and methods The study groups were assembled from The South East Region Prostate Cancer Register (SERPCR), and The Scandinavian Prostate Cancer Group (SPCG) Trial No. 5. In the first study, prognostic factors and long-term disease-specific mortality rates of low-risk prostate cancer patients from the early PSA era were analysed. In the second study, patient-related factors, quality-of-life (QoL) and long-term survival in 915 PCa patients with bone metastases (M1b) under ADT, were analysed. In Study III factors predicting primary failure to respond to ADT were identified. Study IV explored the impact of the extent of bone metastases on survival and QoL for these men. Result and conclusions The long-term disease-specific mortality of low-risk localised PCa is low, but the annual mortality rate gradually increases. This indicates that some tumours slowly develop into lethal cancer, particularly in men 70 years or older and with a PSA level ≥ 4 μg/L. From the SPCG Trial No. 5, a subgroup of patients with M1b disease and favourable set of predictive factors survived more than 10 years under ADT with an acceptable QoL. Independent predictors of long-term survival were identified as performance status (PS) < 2, limited extent of bone metastases, and a PSA level < 231 μg/L at the time of enrolment in the trial. However, four independent clinical predictors of early ADT failure could be defined. Men exhibiting these features should be considered for an alternative treatment. Patient grouping based on three categories of extent of bone metastases related to PS, haemoglobin, and QoL at presentation, as independent predictors of mortality, may provide improved accuracy of prognosis.
APA, Harvard, Vancouver, ISO, and other styles
4

Holmström, Benny. "Early diagnosis and treatment of prostate cancer : observational studies in the National Prostate Cancer Register of Sweden and the Västerbotten Intervention Project." Doctoral thesis, Umeå universitet, Urologi och andrologi, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-42843.

Full text
Abstract:
Prostate-specific antigen (PSA) testing has caused a steep increase in the incidence of prostate cancer, especially the incidence of localised low risk disease. In order to decrease the overdiagnosis accompanied by PSA testing, analysis of inherited genetic variants have been suggested as potential tools for clinical assessment of disease risk. With the aim of minimizing overtreatment and postpone side-effects of curative treatment for low risk prostate cancer, active surveillance, a treatment strategy with initial surveillance and deferred radical prostatectomy at the time of progression has evolved.  The aim of this thesis was to study the validity of PSA (paper I) and inherited genetic variants (paper II) for early diagnosis of prostate cancer, to assess the extent of PSA testing in Sweden (paper III), and to study the safety of deferred radical prostatectomy in localised low to intermediate risk prostate cancer (paper IV). The study designs were i) case-control studies nested within the Västerbotten intervention project (paper I and II), ii) observational study in the Cancer Register of Sweden (paper III), and iii) observational study in the NPCR Follow-up study (paper IV). PSA had a high validity in predicting a prostate cancer diagnosis with an area under the receiver operating characteristics (ROC) curve of 0.86 (95% CI, 0.84 to 0.88). A combined test, including PSA, the ratio of free to total PSA, and 33 single nucleotide polymorphisms (SNPs) in a genetic risk score, increased the area under curve to 0.87 (95% CI, 0.85 to 0.89). The estimated uptake of PSA testing among men aged 55 to 69 years increased from zero to 56% between 1997 and 2007 and there were large variations in the uptake of PSA testing between counties in Sweden. After a median follow-up time of eight years there was no significant difference in presence of any one or more adverse pathology features or prostate cancer specific mortality after primary compared to deferred radical prostatectomy in localised low to intermediate risk prostate cancer. Results from these studies indicate that PSA and the hitherto identified SNPs are not suitable biomarkers in single-test prostate cancer screening. It is possible to estimate the uptake of PSA testing on a population level. Initial surveillance and deferred radical prostatectomy represent a feasible treatment strategy in localised low to intermediate risk prostate cancer.
APA, Harvard, Vancouver, ISO, and other styles
5

Bjerke, Jeanette. "Att dö med trycksår." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-161984.

Full text
Abstract:
Bakgrund: Trycksår är en lokal skada av huden. Skadan ligger ovanför ett benutskott och orsakas av tryck eller en kombination av tryck skjuvning eller friktion. Smärta från trycksåret är ett vanligt förekommande problem som påverkar livskvaliteten negativt. Syfte: Syftet med studien var att undersöka förekomsten av trycksår i livets slutskede samt att se om personer med smärta och trycksår är smärtskattade med VAS/NRS. Syftet var även att se om det fanns något samband mellan trycksår och smärta. Metod: Metoden som använts var en retrospektiv deskriptiv undersökning med kvantitativ ansats. Insamling av data skedde via frågor tagna ur dödsfallsenkäten. Uppgifterna togs ur Svenska palliativregistret samt via journalgranskning. Resultat: Förekomsten av trycksår under 2008-2010 var mellan 29 - 33 %. Under perioden dog 95 (30 %) personer med trycksår, 83 % av dessa trycksår var kategori 1 eller 2 sår. Av de som avled med trycksår upplevde 78 % smärta sista veckan i livet, 59 % hade smärtskattats med VAS/NRS där det visade sig att 69 % skattade över 3 på VAS/NRS skalan. Medianen på VAS/NRS var 6. Inget signifikant samband mellan trycksår och smärta påvisades. Slutsats: Personal som vårdar personer i livets slutskede bör ha en god kunskap om hur, var­för och när trycksår uppkommer mot slutet av livet och även ha ökad kunskap om kroppens smärtmekanismer samt vilken symtomlindring som fungerar. Nyckelord: god död, palliativvård, cancer, Svenska palliativregistret.
Background: Pressure ulcers are a local damage of the skin. The damage is above a bony prominence caused by pressure or a combination of pressure shear and friction. Pain from the pressure ulcer is a common problem that affects quality of life negatively. Aim: The aim of this study was to investigate the incidence of pressure ulcers in palliative care and to see if people with pain and pressure ulcers are pain assessed by VAS/NRS. The aim was also to see if there was any correlation between pressure ulcers and pain. Method: The method used was a retrospective descriptive study with quantitative approach. Data collection was done through questions taken from the Swedish death inquiry. The data were taken from the Swedish palliative register and through journal review. Results: The incidence of pressure ulcers during 2008-2010 was between 29 – 33 %. During the period died 95 (30%) with pressure ulcers, 83% of these pressure ulcers were category 1 or 2 wounds. Of those who died with pressure ulcers 78 % experienced pain last week of life, 59 % had pain assessed by VAS/NRS that showed that 69% estimated above 3 on the VAS/NRS scale. The median on VAS/NRS was 6. No significant correlation between pressure ulcers and pain were found. Conclusion: Staff who care for people in end of life care should have a good knowledge of how, why and when pressure ulcers occur towards the end of life, they should also have greater knowledge of the body's pain mechanisms and pain relief that works. Keywords: Good death, palliative care, cancer, Swedish palliative register.
APA, Harvard, Vancouver, ISO, and other styles
6

Martinsson, Lisa. "Quality improvement in palliative care : the role of a national quality register and perceptions of information during palliative chemotherapy." Doctoral thesis, Umeå universitet, Onkologi, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-102264.

Full text
Abstract:
Introduction There is a need in palliative care for development of structured methods to assess quality and support improvement. This need is present both within and outside specialised palliative care. Honest information from physicians is regarded as an important part of palliative care. Information about the transition to end-of-life care (ITEOL), conveyed by physicians to patients, has also been described as a ‘breakpoint conversation’. Quality registers enable monitoring and improvement of quality of care, and clinical research. The Swedish Register of Palliative Care (SRPC) is a Swedish national quality register that collects data from hospitals, hospices, nursing homes and home care, with an end-of-life questionnaire (ELQ) about palliative care content focusing on the last week of life. Aims Study I – The aim was to examine the validity of the ELQ from the SRPC. Study II – The aim was to examine whether participation in the SRPC increases the quality of palliative care over a three-year period regarding eight items in the ELQ. Study III – The aim was to examine whether an educational intervention for physicians and nurses in nursing homes and hospitals increases the proportion of patients who receive ITEOL. Study IV – The aim was to describe how patients with cancer perceive the information they receive from physicians during palliative chemotherapy. Methods Study I – Data from 100 medical records and data from the paper versions of the ELQ filled in at a specialised palliative unit were compared with data reported to the SRPC. Study II – Data from eight items in the ELQ reported to the SRPC from all healthcare units that had reported patients continuously during a three-year period were compared year-by-year with logistic regression. Study III – Two municipalities (in charge of nursing homes) and two hospitals were randomised to receive an interactive half-day course about ITEOL for physicians and nurses. Four hospitals and four municipalities were assigned matched controls. The proportion of patients who received ITEOL before and after the intervention was measured with the ELQ. The effect of the intervention was analysed with a multivariable logistic regression model. Study IV – Fifteen semi-structured interviews with patients with incurable cancer were conducted, transcribed verbatim and analysed with qualitative content analysis. Results Study I – The questions in the ELQ showed a congruity of 22% to 100% when comparing data from medical records with data reported to the SRPC. Eight questions fell below 80%. The paper versions filled in at the unit and the data reported to the SRPC showed a congruity of between 91% and 100%. Study II – The prevalence of six symptoms decreased. The prescription of PRN (pro re nata – ‘as needed’) medications for pain, nausea, anxiety and death rattle increased. A higher proportion of patients died in their place of preference. The patient’s next of kin was more often offered a follow-up appointment after the patient’s death. There was no change in the proportion of patients or next of kin who received ITEOL. Study III – The proportion of patients in the intervention group who received ITEOL increased from 35.1% (during a six-month period before the intervention) to 42.0% (during a six-month period after the intervention). The proportion in the control group increased from 30.4% to 33.7%. The effect of the intervention was significant (p=0.005) in the multivariable model. Study IV – Three categories were disclosed during the analytical process: ‘living with a death sentence’, ‘depending on chemotherapy’, and ‘living with uncertainty’. Conclusions A national quality register has the potential of contributing to quality improvement in palliative care. Study I showed varied validity in the ELQ, implying a need to modify the questionnaire. Study II showed that participation in the SRPC was covariant with quality improvements in end-of-life care over time. Study III showed that more patients received ITEOL after an educative half-day intervention directed to physicians and nurses. Study IV showed that patients undergoing palliative chemotherapy perceived that their disease was incurable and deadly, and that conditions for future treatment and survival were uncertain.
APA, Harvard, Vancouver, ISO, and other styles
7

Roué, Tristan. "Épidémiologie des cancers en Guyane : Analyse des données du registre des cancers de Guyane." Thesis, Antilles-Guyane, 2014. http://www.theses.fr/2014AGUY0743/document.

Full text
Abstract:
L'objectif du registre des cancers de Guyane est de collecter l ensemble des tumeurs invasives et/ou in situ survenues depuis le 1er janvier 2003 chez des patients vivant en Guyane, quels que soient la localisation de la tumeur, le lieu de diagnostic et de traitement. Cette thèse a pour but de décrire la population atteinte d un cancer afin d améliorer les connaissances sur cette maladie et ainsi de permettre aux actions de santé publique d être plus efficaces.De 2003 à 2009, le taux d incidence des cancers standardisé sur l âge était, dans les deux sexes, 30% inférieur en Guyane par rapport à la France métropolitaine et n était pas différent de celui d Amérique du Sud.Nous avons comparé l incidence, la mortalité et la survie relative des patientes atteintes d un cancer invasif du sein (CIS) et des patientes atteintes d un cancer invasif du col de l utérus (CIC) entre la Guyane et la métropole.Le ratio incidence/mortalité indiquait que les cancers du sein étaient de plus mauvais pronostic en Guyane par rapport à la métropole.La survie relative des femmes atteintes d un CIS était inférieure en Guyane par rapport à la France métropolitaine.En Guyane, le taux standardisé d incidence du cancer du col de l utérus était 4 fois plus élevé qu en métropole. Les femmes vivant dans l intérieur de la Guyane semblaient être diagnostiquées à un stade plus tardif et plus souvent sur symptômes que les femmes du littoral. L accès aux soins des migrants est un challenge et une source d inégalité de santé. La détection précoce des cancers à travers des programmes de prévention est cruciale pour améliorer la survie par cancer et notamment chez les patients étrangers
The objective of the cancer registry of French Guiana is to compile all patients living in French Guiana with malignant invasive pathology and/or in situ lesions starting January 1st 2003 in persons living in French Guiana, whatever the tumoral location and the place of diagnosis and care. This study aimed to describe the population with invasive cancer to improve the knowledge about this disease in order to target public health interventions more effectively.The age standardised incidence rate was 30% times lower than in France in both sexes and the same than in South America.We compared incidence and relative survival of patients with invasive breast cancer (IBC) and patients with invasive cervical cancer (ICC) between women from French Guiana and metropolitan France.The ratio between incidence and mortality showed that the prognosis of IBC in French Guiana was worse than in metropolitan France.The relative survival rate among women with IBC in French Guiana was lower than among women in metropolitan France.In French Guiana, the age-standardized incidence rate of cervical cancer was four times higher than in France. Women living in remote areas seemed to be diagnosed later and more often following symptoms.Access to care for migrants is challenging and sustains health inequalities. Early detection through prevention programs is crucial for increasing cancer survival notably for foreign-born patients. Further studies with more patients and other variables could improve the knowledge about these diseases
APA, Harvard, Vancouver, ISO, and other styles
8

Stoebner, Anne. "Le registre des tumeurs de l'Hérault : incidence 1986-1988 : comparaisons avec les principaux registres français." Montpellier 1, 1991. http://www.theses.fr/1991MON11050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Arnaud, Catherine. "Analyse comparative des méthodes d'évaluation de l'exhaustivité des registres de tumeurs : propositions pour le registre de l'Hérault." Montpellier 1, 1992. http://www.theses.fr/1992MON11040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Puyade, Mathieu. "Parcours de soins des patients atteints d'hémopathies malignes en Poitou-Charentes." Thesis, Poitiers, 2017. http://www.theses.fr/2017POIT1407/document.

Full text
Abstract:
La réduction des inégalités d'accès aux soins a toujours été un axe majeur des politiques de lutte contre le cancer. Alors qu'il existe de nombreuses études en cancérologie solide, peu d'études avec une méthodologie correcte existent en onco-hématologie, notamment chez les patients atteints de Myélome Multiple (MM). Cette maladie a vu son pronostic transformé par l'arrivée de nouvelles thérapeutiques dont l'usage a été rapidement intégré dans les recommandations de la Société Française d'Hématologie. L'objectif de travail intitulé Parcours de Soins des patients atteints d'hémopathie maligne en Poitou Charentes était donc de décrire et d'analyser les écarts aux recommandations, en prenant le MM comme premier exemple. Grâce au registre des Cancers Poitou-Charentes et à l'exhaustivité des cas qu'il assure, notre travail a permis de déterminer des variables associées à une inégalité d'accès aux soins. Ces variables sont démographiques (âge, distance entre le domicile et l'hôpital), liées à la tumeur (maladie symptomatique ou non), mais aussi organisationnelles (niveau de l'hôpital, passage en réunion de concertation pluridisciplinaire). De plus nous avons pu montrer que ces inégalités avaient un impact sur la survie globale des patients, notamment chez les plus âgés. Notre travail se poursuit par une analyse plus fine de la survie globale et l'étude des longs survivants du Myélome Multiple. A plus long terme, nous souhaitons appliquer cette approche à d'autres hémopathies
French national Cancer plans aimed to reduce health care inequalities. These inequalities are well known in solid cancers but few data with correct methodology exist in Hematology, especially in Multiple Myeloma (MM). The new treatments in this disease have dramatically improved Overall Survival. So guidelines of the Société Française d'Hématologie have quickly recommended the use of these new drugs. The aim of our work: Care Pathway of patients with hematological malignancies in Poitou Charentes area was to describe and analyze non compliance to guidelines. Based on the exhaustivity of the Poitou Charentes Cancer Registry, our work revealed variables associated with healthcare inequalities. They were demographical (age, distance between home and hospital), tumor-related (symptomatic MM or not) but also organizational (level of the hospital, multidisciplinary meeting). Moreover we showed that those inequalities had a negative impact on overall survival, especially in elderly people. Our work continues with more accurate analysis of overall survival and a study on MM long survivors. Longer-term studies would be to transfer this approach to other hemopathies
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer Register"

1

Registry, National Cancer. Cancer in Ireland, 1995: Incidence and mortality : report of the National Cancer Registry. Cork: National Cancer Registry Board, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Registry, National Cancer. Cancer in Ireland, 1994: Incidence and mortality : report of the National Cancer Registry. Cork: National Cancer Registry Board, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Registry, National Cancer. Cancer in Ireland, 1996: Incidence and mortality. Cork: National Cancer Registry Board, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Great Britain. Office of Population Censuses and Surveys., ed. Cancer statistics: Registrations : cases of diagnosed cancer registered in England and Wales. London: H.M.S.O., 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Great Britain. Office of Population Censuses and Surveys., ed. Cancer statistics, registrations: Cases of diagnosed cancer registered in England and Wales. London: H.M.S.O., 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Great Britain. Office of Population Censuses and Surveys., ed. Cancer statistics, registrations: Cases of diagnosed cancer registered in England and Wales. London: H.M.S.O., 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Great Britain. Office of Population Censuses and Surveys., ed. Cancer statistics: Registrations : cases of diagnosed cancer registered in England and Wales, 1982. London: H.M.S.O., 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Registry, California Cancer. Research utilizing the California Cancer Registry. Sacramento, CA: California Dept. of Health Services, Cancer Surveillance Section, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Division, Texas Cancer Registry. Cancer Registry Division report, FY 1986. [Austin]: Texas Dept. of Health, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ch, Witting, ed. Möglichkeiten für den Aufbau eines berufsbezogenen Tumor-Registers: Theoretische Ansätze und erste Erfahrungen. Dortmund: Bundesanstalt für Arbeitsschutz, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer Register"

1

"Register." In Current Cancer Research 1986, 253–55. Heidelberg: Steinkopff, 1986. http://dx.doi.org/10.1007/978-3-662-21737-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chambers, Ruth, and Gill Wakley. "Cancer 1: register." In Clinical Audit in Primary Care, 116–19. CRC Press, 2018. http://dx.doi.org/10.1201/9781315378145-22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Action Cancer." In The Grants Register 2023, 14. London: Palgrave Macmillan UK, 2022. http://dx.doi.org/10.1057/978-1-349-96053-8_16414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Cancer Immunotherapy." In The Grants Register 2023, 283–85. London: Palgrave Macmillan UK, 2022. http://dx.doi.org/10.1057/978-1-349-96053-8_9721.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Action Cancer." In The Grants Register 2020, 9. London: Palgrave Macmillan UK, 2019. http://dx.doi.org/10.1057/978-1-349-95943-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Cancer Immunotherapy." In The Grants Register 2020, 230–31. London: Palgrave Macmillan UK, 2019. http://dx.doi.org/10.1057/978-1-349-95943-3_228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

"Action Cancer." In The Grants Register 2021, 10–11. London: Palgrave Macmillan UK, 2020. http://dx.doi.org/10.1057/978-1-349-95988-4_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Cancer Immunotherapy." In The Grants Register 2021, 248. London: Palgrave Macmillan UK, 2020. http://dx.doi.org/10.1057/978-1-349-95988-4_231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Action Cancer." In The Grants Register 2022, 14. London: Palgrave Macmillan UK, 2021. http://dx.doi.org/10.1057/978-1-349-96042-2_16514.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"Cancer Immunotherapy." In The Grants Register 2022, 269–70. London: Palgrave Macmillan UK, 2021. http://dx.doi.org/10.1057/978-1-349-96042-2_9821.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer Register"

1

Gonzalez-Cao, Maria, Cristina Carrera, Juan Francisco Rodriguez Moreno, Pedro Rodriguez-Jiménez, Mónica Antoñanzas Basa, Marta Feito Rodríguez, Teresa Puertolas, et al. "Abstract PO-059: COVID-19 in melanoma patients: Spanish register." In AACR Virtual Meeting: COVID-19 and Cancer; July 20-22, 2020. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.covid-19-po-059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Petersen, Kajsa, Julie Elbæk Pedersen, Johnni Hansen, Niels Ebbehøj, and Jens Peter Bonde. "P044 A register based cohort study of cancer in danish firefighters." In Occupational Health: Think Globally, Act Locally, EPICOH 2016, September 4–7, 2016, Barcelona, Spain. BMJ Publishing Group Ltd, 2016. http://dx.doi.org/10.1136/oemed-2016-103951.368.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sinn, M., C. Pollich, S. Bischoff, E. Wolters, E. Späth-Schwalbe, C. Leng, M. de Wit, et al. "GECAT - German Evaluation of Cancer associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism in Berlin." In 63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680127.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Liu, Zhiwei, Fang Fang, Ellen T. Chang, and Weimin Ye. "Abstract 2758: Cancer risk in relatives of nasopharyngeal carcinoma - A register-based cohort study in Sweden." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2758.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pochetti, Patrizia, Lorenza Conti, Valentina Foci, Filippo Patrucco, Anna Maria Calareso, Giulia Rovere, Jaber Mohamad, and Mario Malerba. "More than Kidney Failure in Obstructive Sleep Apnea: Urinary Tract Cancer Data from the Vercelli Register." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa906.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Scheulen, Max E., Bahar Nokay, Heike Richly, Andreas C. Hoffmann, Janine Kalkmann, Joerg Stattaus, Norbert Bornfeld, Martin Schuler, and Joerg Hense. "Abstract C185: Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-c185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dimopoulos, Alexandros C., John Lakoumentas, Argyro Antaraki, Antonios Frigas, Emmanouil K. Ikonomakis, Marinos Sampson, Anastasios Tagaris, et al. "e-Prolipsis: A web based risk estimation platform to support and register breast cancer diagnosis in Greece." In 2012 IEEE 12th International Conference on Bioinformatics & Bioengineering (BIBE). IEEE, 2012. http://dx.doi.org/10.1109/bibe.2012.6399765.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jakobsen, Jarle, Marit B. Veierød, Kristina Kjaerheim, Tom K. Grimsrud, Sophie Dorothea Fosså, and Bato Hammarström. "O-392 Early detection of prostate cancer in firefighters – a register-based study of prognostic factors and survival." In 28th International Symposium on Epidemiology in Occupational Health (EPICOH 2021). BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/oem-2021-epi.21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Løkke, Anders, Jeyanthini Risikesan, Anja Gouliaev Kirkeby, and Ole Hilberg. "Direct and indirect economic and health consequences of Lung cancer in Denmark: a national register-based study: 1998–2010." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2610.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jagdish, R., N. Haslam, and A. Bassi. "VETTING BY GENETIC COUNSELLORS IMPROVES APPROPRIATENESS OF COLONOSCOPY FOR PATIENTS ON SURVEILLANCE REGISTER WITH FAMILY HISTORY OF COLORECTAL CANCER." In ESGE Days. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1704797.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer Register"

1

Yan, Miao, Shuang Xia, and Yichang Zhao. Risk of sepsis in cancer patients treated with immune checkpoint inhibitors: a safety meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0174.

Full text
Abstract:
Review question / Objective: The aim of this meta-analysis is to estimate the risk of sepsis in cancer patients treated with immune checkpoint inhibitors in randomized controlled trials (RCTs). Condition being studied: Sepsis-related toxicities in cancer patients received immune checkpoint inhibitors. Information sources: Electronic databases:Medline; Embase; Central; Trial registers: ClinicalTrails.gov. EU Clinical Trials Register. International Clinical Trials Registry Platform. Regarding RCTs for which we had neither available adverse events on ClinicalTrials.gov nor available adverse events in publications, corresponding authors or sponsors of the study were contacted by e-mail to provide the required information.
APA, Harvard, Vancouver, ISO, and other styles
2

Whybrow-Huppatz, Isabel, Rachael Walker, Jasjot Maggo, Dianne Murphy, and Suetonia Palmer. Cannabis medicines for symptom management in adults with chronic non-cancer conditions. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0090.

Full text
Abstract:
Review question / Objective: To estimate the benefits and harms of cannabis medicines to manage symptoms in adults with chronic non-cancer conditions. We will conduct a systematic review with meta-analysis of randomised controlled trials. Condition being studied: Chronic non-cancer conditions. Information sources: We will search the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE accessed via Ovid (from 1966), EMBASE accessed via Ovid (from 1980), PschINFO accessed via Ovid (from inception) and LILACS (from inception). Appendix 1 shows the search strategy for Ovid MEDLINE.
APA, Harvard, Vancouver, ISO, and other styles
3

Dy, Sydney M., Arjun Gupta, Julie M. Waldfogel, Ritu Sharma, Allen Zhang, Josephine L. Feliciano, Ramy Sedhom, et al. Interventions for Breathlessness in Patients With Advanced Cancer. Agency for Healthcare Research and Quality (AHRQ), November 2020. http://dx.doi.org/10.23970/ahrqepccer232.

Full text
Abstract:
Objectives. To assess benefits and harms of nonpharmacological and pharmacological interventions for breathlessness in adults with advanced cancer. Data sources. We searched PubMed®, Embase®, CINAHL®, ISI Web of Science, and the Cochrane Central Register of Controlled Trials through early May 2020. Review methods. We included randomized controlled trials (RCTs) and observational studies with a comparison group evaluating benefits and/or harms, and cohort studies reporting harms. Two reviewers independently screened search results, serially abstracted data, assessed risk of bias, and graded strength of evidence (SOE) for key outcomes: breathlessness, anxiety, health-related quality of life, and exercise capacity. We performed meta-analyses when possible and calculated standardized mean differences (SMDs). Results. We included 48 RCTs and 2 retrospective cohort studies (4,029 patients). The most commonly reported cancer types were lung cancer and mesothelioma. The baseline level of breathlessness varied in severity. Several nonpharmacological interventions were effective for breathlessness, including fans (SMD -2.09 [95% confidence interval (CI) -3.81 to -0.37]) (SOE: moderate), bilevel ventilation (estimated slope difference -0.58 [95% CI -0.92 to -0.23]), acupressure/reflexology, and multicomponent nonpharmacological interventions (behavioral/psychoeducational combined with activity/rehabilitation and integrative medicine). For pharmacological interventions, opioids were not more effective than placebo (SOE: moderate) for improving breathlessness (SMD -0.14 [95% CI -0.47 to 0.18]) or exercise capacity (SOE: moderate); most studies were of exertional breathlessness. Different doses or routes of administration of opioids did not differ in effectiveness for breathlessness (SOE: low). Anxiolytics were not more effective than placebo for breathlessness (SOE: low). Evidence for other pharmacological interventions was limited. Opioids, bilevel ventilation, and activity/rehabilitation interventions had some harms compared to usual care. Conclusions. Some nonpharmacological interventions, including fans, acupressure/reflexology, multicomponent interventions, and bilevel ventilation, were effective for breathlessness in advanced cancer. Evidence did not support opioids or other pharmacological interventions within the limits of the identified studies. More research is needed on when the benefits of opioids may exceed harms for broader, longer term outcomes related to breathlessness in this population.
APA, Harvard, Vancouver, ISO, and other styles
4

Wright, William. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, July 1999. http://dx.doi.org/10.21236/ada374022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Young, John L. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, October 1995. http://dx.doi.org/10.21236/ada308093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wright, William. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, October 1997. http://dx.doi.org/10.21236/ada346975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wright, William. California Cancer Registry Enhancement for Breast Cancer Research. Fort Belvoir, VA: Defense Technical Information Center, October 1998. http://dx.doi.org/10.21236/adb249633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zou, Yihua, Fangqin Tong, Meng Guan, Chun Bi, and Xia Wang. Efficacy and safety of Anti-angiogenesis combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: A Meta-Analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0077.

Full text
Abstract:
Review question / Objective: To Systematicly evaluate of the clinical efficacy and safety of the combination of anti-angiogenesis and simultaneous radiotherapy in the treatment of cervical cancer. Condition being studied: Locally advanced cervical cancer. We searched databases including PubMed, Cochrane Library, Embase, Web of Science CNKI, Wanfang, VIP and CBM, and the International Clinical Trial Registry Platform (ICTRP) and the Chinese Clinical Registry(ChiCTR) to collect the clinical studies about the randomized controlled trial (RCTS) of anti-angiogenic drugs (mainly Endu, apatinib and bevacizumab) combined with chemoradiotherapy in the treatment of cervical cancer. The time limit is from the establishment of the database to April 2022. RevMan 5.4 software was used to analyze the short-term efficacy and the incidence of adverse reactions.
APA, Harvard, Vancouver, ISO, and other styles
9

Foster, Stephanie, Amy M. Lavery, Suzanne K. Condon, Alisha Etheredge, Kennedy Brian, Svendsen Erik, and Breysse Patrick. Guidelines for examining unusual patterns of cancer and environmental concerns. National Center for Environmental Health (U.S.), December 2022. http://dx.doi.org/10.15620/cdc:122695.

Full text
Abstract:
The Centers for Disease Control and Prevention (CDC) National Center for Environmental Health (NCEH) and the Agency for Toxic Substances and Disease Registry (ATSDR) provide scientific guidance to state, tribal, local, and territorial (STLT) health departments related to environmental health concerns. The guidelines presented here update the 2013 publication, “Investigating Suspected Cancer Clusters and Responding to Community Concerns: Guidelines from the CDC and the Council of State and Territorial Epidemiologists (CSTE)”.1 In general, STLT health departments play the primary role in examining unusual patterns of cancer in communities, including those associated with local environmental concerns. These guidelines expand the approach for these investigations. Occupation-related clusters are not included in these guidelines. Publication date from document properties. CS336302-A Guidelines-for-Examining-Unusual-Patterns-of-Cancer-and-Environmental-Concerns-h.pdf
APA, Harvard, Vancouver, ISO, and other styles
10

Levine, Paul H. The Establishment of an Inflammatory Breast Cancer Registry and Biospecimen Repository. Fort Belvoir, VA: Defense Technical Information Center, August 2004. http://dx.doi.org/10.21236/ada432933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer Register' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography